1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Cell Therapies, Biosimilars Boost Biologics Clinical Trials In Korea

 
• By Jung Won Shin

South Korean clinical trial data for 2016 reflects the global boom in biologics R&D and the decline in development of synthetic drugs. A series of clinical trial failures by major South Korean pharmaceutical firms may also have weakened overall drug development activities.

Scientist

Despite a drop in overall clinical trial approvals in South Korea last year, trials for biologics continued to climb, reflecting robust R&D activities in biosimilars and cell therapies on the back of the government's support for the biotech industry.

The Ministry of Food and Drug Safety has granted 226 approvals for clinical trials of biologics last year, up from 202 a year earlier

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK Mandates Unmodified Standardized Contracts To Speed Clinical Trial Set-Up

 
• By Vibha Sharma

The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview.